Serous high-grade ovarian carcinoma with a complete loss of SMARCA2 expression.
Staining Pattern in Normal Tissues
Manual protocol
Freshly cut sections should be used (less than 10 days between cutting and staining). Heat-induced antigen retrieval for 5 minutes in an autoclave at 121°C in pH 7,8 Target Retrieval Solution buffer. Apply HMV337 at a dilution of 1:200 at 37°C for 60 minutes. Visualization of bound antibody by the EnVision Kit (Dako, Agilent) according to the manufacturer’s directions.
| Brain | Cerebrum, grey | Negative | |
| Cerebrum, white | Negative | ||
| Cerebellum, cortex | Negative | ||
| Cerebellum, white | Negative | ||
| Ganglion | Negative | ||
| Ependyma | Negative | ||
| Eye, retina | Negative | ||
| Endocrine Tissues | Thyroid | Nuclear SMARCA2 staining of all cells. | |
| Parathyroid gland | Nuclear SMARCA2 staining of all cells. | ||
| Adrenal gland | Nuclear SMARCA2 staining of all cells. | ||
| Pituitary gland, anterior lobe | Negative | ||
| Pituitary gland, posterior lobe | Negative | ||
| Respiratory system | Lung bronchi | Negative | |
| Lung, bronchial glands | Negative | ||
| Nose, paranasal sinus | Negative | ||
| Lung, parenchyma | Negative | ||
| Proximal digestive tract | Lip | Negative | |
| Oral cavity | Negative | ||
| Tonsil, surface | Negative | ||
| Esophagus, mucosa | Negative | ||
| Lip, small salivary gland | Negative | ||
| Sublingual gland | Negative | ||
| Parotid gland | Negative | ||
| Submandibullary gland | Negative | ||
| Gastronintestinal tract | Stomach, antrum | Negative | |
| Stomach, fundus and corpus | Negative | ||
| Small intestine, duodenum | Negative | ||
| Duodenum, Brunner gland | Negative | ||
| Small intestine, ileum | Negative | ||
| Appendix | Nuclear SMARCA2 staining of all cells. | ||
| Colon descendens | Negative | ||
| Rectum | Nuclear SMARCA2 staining of all cells. The staining is somewhat weaker in surface epithelium than in the crypts. | ||
| Anal canal, transition epithelium | Negative | ||
| Liver, Gallbladder, Pancreas | Liver | Nuclear SMARCA2 staining of all cells. Staining is weakest in hepatocytes. | |
| Gallbladder | Nuclear SMARCA2 staining of all cells. | ||
| Pancreas | Nuclear SMARCA2 staining of all cells. | ||
| Kidney, urinary bladder | Kidney, cortex | Negative | |
| Kidney, medulla | Negative | ||
| Urinary bladder, urothelium | Negative | ||
| Kidney pelvis, mucosa | Negative | ||
| Male tissues | Prostate | Nuclear SMARCA2 staining of all cells. | |
| Seminal vesicle | Negative | ||
| Epididymis caput | Negative | ||
| Epididymis cauda | Negative | ||
| Testis | Nuclear SMARCA2 staining of most cells, but Sertoli cells remain SMARCA2 negative. | ||
| Female Tissues | Breast, glands | Negative | |
| Ectocervix | Negative | ||
| Endocervix | Negative | ||
| Endometrium, proliferation | Negative | ||
| Endometrium, secretion | Negative | ||
| Uterus, myometrium | Nuclear SMARCA2 staining of all cells. | ||
| Fallopian tube | Nuclear SMARCA2 staining of all cells. | ||
| Ovary, stroma | Negative | ||
| Ovary, follicular cyst | Negative | ||
| Ovary, corpus luteum | Negative | ||
| Amnion | Nuclear SMARCA2 staining of all cells. | ||
| Chorion | Nuclear SMARCA2 staining of all cells. | ||
| Amnion/Chorion | Negative | ||
| Placenta, early, decidua | Negative | ||
| Placenta, first trimenon | Negative | ||
| Placenta, mature | Nuclear SMARCA2 staining of all cells but staining is somewhat reduced in cytotrophoblast cells. | ||
| Muscle, connective & soft tissue | Aorta, intima | Negative | |
| Skeletal muscle | Nuclear SMARCA2 staining of all cells. | ||
| Aorta, media | Negative | ||
| Skeletal muscle, tongue | Negative | ||
| Heart, left ventricle | Negative | ||
| Kidney pelvis, muscular wall | Negative | ||
| Urinary bladder, muscular wall | Negative | ||
| Esophagus, muscular wall | Negative | ||
| Stomach, muscular wall | Negative | ||
| Ileum, muscular wall | Negative | ||
| Appendix, muscular wall | Negative | ||
| Colon descendens, muscular wall | Negative | ||
| Penis, glans, corpus spongiosum | Negative | ||
| Fat, white | Negative | ||
| Skin | Skin, surface | Negative | |
| Skin (hairs, sebaceous glands) | Negative | ||
| Anal canal, skin | Negative | ||
| Scrotum | Negative | ||
| Bone Marrow & lymphoid tissues | Bone marrow | Nuclear SMARCA2 staining of all cells. | |
| Thymus | Nuclear SMARCA2 staining of all cells. | ||
| Spleen | Nuclear SMARCA2 staining of all cells. | ||
| Lymph node | Nuclear SMARCA2 staining of all cells. | ||
| Tonsil, deep | Negative |
Details
More product details
More product details
Biology behind
SMARCA2 (SWI/SNF‐related matrix‐associated actin‐dependent regulator of chromatin subfamily A member 2) is coded by the SMARCA2 gene located at chromosome 9p24.3. Along with SMARCA4, SMARCA2 is one of two mutually exclusive, exchangeable DNA-dependent ATPases, which constitute the enzymatic motor of a polymorphic family of SWI/SNF complexes which also include 8–15 further subunits (). SWI/SNF can modify the transcription of genes by altering the chromatin structure surrounding them. SMARCA2 is ubiquitously expressed in the nuclei of normal cells. Mutations in individual members of the SWI/SNF family together represent one of the most common genetic alterations in cancer, observed in about 20% of cases. According to public databases, mutations of SMARCA2 are rare but SMARCA2 downregulation in cancer can occur due to alternative mechanisms. Targeting SMARCA2 may cause synthetic lethality in SMARCA4 deficient cancers.
Protocol Recommendations
Protocol Recommendations
Potential Research Applications
Potential Research Applications
Evidence For Antibody Specificity In I H C
Evidence For Antibody Specificity In I H C
